News & Updates
Excerpt from the Press Release: CAMBRIDGE, Mass. & BRISBANE, Australia–(BUSINESS WIRE)–Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology. The vaccine being delivered by…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass., Feb. 10, 2023 /PRNewswire/ — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that an independent Data Monitoring Committee (DMC) completed its prespecified review of interim…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetralstat for the on-demand treatment of…
Read More
VST-Bio’s Collaborators Present Preclinical Trial Results at the American Heart Association International Stroke Conference in Dallas. Excerpt from the Press Release: SAN DIEGO, Feb. 10, 2023 /PRNewswire/ — VST-Bio Corp. a leader in the development of innovative biologics to treat acute and chronic cardiovascular disease, presented data from a recent large animal study performed by…
Read More
Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept More Vabysmo patients showed an absence of blood vessel leakagein the retina compared to aflibercept in a pre-specified exploratory endpoint If approved, RVO would be the third indication for Vabysmo in addition to wet, or…
Read More
Addressing the Need for the Rapid Non-subjective, Digitized Detection of Ebola and Ebola Family Viruses Excerpt from the Press Release: CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ — DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, today announced a subcontract with Mapp Biopharmaceutical, Inc., a developer of novel pharmaceuticals…
Read More
Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / February 1, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that two IND-enabling toxicology studies have been completed in non-human primates (NHPs) using its lead bifunctional therapeutic candidate. SON-1210 is a proprietary, bispecific…
Read More
Expects to Commence Phase 2a of CAReS During the First Quarter of 2023 Excerpt from the Press Release: SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that enrollment in…
Read More
Acquisition eliminates all future royalty payment obligations for PH94B and PH10 and expands Vistagen’s pipeline Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing…
Read More
Dosing marks first time a computationally designed monoclonal antibody enters human trial in the U.S. U.S. enrollment begins in North Carolina, with additional sites being planned nationwide Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?